🟢 Adaptive Biotechnologies is trading 6.55% up in pre-market after unexpected Q3 profit

Adaptive Biotechnologies is trading 6.55% higher at $28.46 after reporting unexpected third-quarter profitability.

• Third-quarter revenue of $83.9 million beat estimates, and management raised its full-year MRD revenue outlook to $276 million–$286 million.
• The company reported $2.8 million in GAAP net income.
• clonoSEQ test volume grew 46% year over year; pre-market strength in the biotech sector may also support the move.